Verrica Pharmaceuticals Inc (NASDAQ:VRCA) COO Linda Palczuk bought 3,000 shares of Verrica Pharmaceuticals stock in a transaction that occurred on Wednesday, January 16th. The shares were acquired at an average cost of $10.53 per share, for a total transaction of $31,590.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of NASDAQ:VRCA opened at $10.42 on Friday. Verrica Pharmaceuticals Inc has a 1 year low of $6.44 and a 1 year high of $23.29.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its earnings results on Wednesday, November 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.03). As a group, equities research analysts anticipate that Verrica Pharmaceuticals Inc will post -1.17 earnings per share for the current year.

Separately, Zacks Investment Research raised Verrica Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, December 13th.

A number of large investors have recently made changes to their positions in the stock. FMR LLC bought a new stake in Verrica Pharmaceuticals in the 2nd quarter worth about $21,703,000. Laurion Capital Management LP purchased a new position in Verrica Pharmaceuticals in the second quarter worth about $395,000. Gilder Gagnon Howe & Co. LLC boosted its position in Verrica Pharmaceuticals by 12.4% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 167,574 shares of the company’s stock worth $2,723,000 after purchasing an additional 18,530 shares during the last quarter. Asymmetry Capital Management L.P. boosted its position in Verrica Pharmaceuticals by 28.1% in the third quarter. Asymmetry Capital Management L.P. now owns 76,885 shares of the company’s stock worth $1,249,000 after purchasing an additional 16,885 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in Verrica Pharmaceuticals in the third quarter worth about $195,000. 32.07% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Verrica Pharmaceuticals Inc (VRCA) COO Acquires $31,590.00 in Stock” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://theolympiareport.com/2019/01/20/verrica-pharmaceuticals-inc-vrca-coo-acquires-31590-00-in-stock.html.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790.

Read More: Net Income

Insider Buying and Selling by Quarter for Verrica Pharmaceuticals (NASDAQ:VRCA)

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.